| 生物活性 |
Carvacryl acetate is an orally active TRPA1 receptor activator and Na+/K+-ATPase activator that crosses the blood-brain barrier, modulates GABAergic signaling pathways, alters GABA and glutamine levels in hippocampal tissue, reduces lipid peroxidation and nitrite production, scavenges hydroxyl radicals, and enhances glutathione and antioxidant enzyme activity, while also inhibiting larval hatching, development, adult motility, and fecal egg counts of Haemonchus contortus and causing structural damage to adult worms, and is therefore useful for research on intestinal mucositis, gastrointestinal nematode infections, epilepsy, and neurodegenerative diseases. |
体内研究 (In Vivo) |
Carvacryl acetate (25-150 mg/kg;腹腔注射;每天一次,连续八天) 对雌性 Swiss 小鼠中 Irinotecan (MS-O02109) 诱导的肠黏膜炎表现出强效的抗炎和抗氧化功效,其中 75 mg/kg 腹腔注射剂量可实现 100%存活率,并通过激活 TRPA1 受体将关键的组织学、炎症和氧化应激参数恢复至接近正常水平。 Carvacryl acetate (500-4000 mg/kg;口服;单次给药) 在雌性 Swiss albino 小鼠中表现出较低的急性口服毒性,其 LD50 为 1544.5 mg/kg。 Carvacryl acetate (250 mg/kg;口服;单次给药) 在单次口服 250 mg/kg 剂量后第 16 天,可使自然感染胃肠道线虫的绵羊粪便虫卵数减少 65.9%。 Carvacryl acetate (100 mg/kg;腹腔注射;单次给药;Pilocarpine 给药前 30 分钟) 对 Pilocarpine (MS-U99376) 诱导的小鼠癫痫发挥抗惊厥作用,可使癫痫发作率降低 60%、死亡率降低 40%,使癫痫发作潜伏期延长 340.55%,并通过 GABA 能介导的机制改善海马区酶类及 GABA 水平。 Carvacryl acetate (100 mg/kg;腹腔注射;单次给药;pentylenetetrazol 给药前 30 分钟) 对小鼠 pentylenetetrazol 诱导的癫痫具有抗惊厥作用,可分别使癫痫发作和死亡率降低 70%,使癫痫发作潜伏期延长 345.96%,并通过 GABA 能介导的机制改善海马酶和 GABA 水平。 Carvacryl acetate (100 mg/kg;腹腔注射;单次给药;Picrotoxin 给药前 30 分钟) 对 Picrotoxin (MS-F58453) 诱导的小鼠癫痫具有抗惊厥作用,可分别使癫痫发作率和死亡率降低 50%,使癫痫发作潜伏期延长 163.67%,并通过 GABA 能介导的机制改善海马区酶类和 GABA 水平。 Carvacryl acetate (100 mg/kg;腹腔注射;单次给药) 对健康小鼠的自发活动或运动协调性无影响。 Carvacryl acetate (25-100 mg/kg;腹腔注射;单次注射) 在小鼠海马体中表现出强效的体内抗氧化活性,与溶媒对照组相比,100 mg/kg 剂量可使 TBARS 水平降低 85%、亚硝酸盐含量降低 92%、GSH 水平升高 50%、过氧化氢酶活性升高 88%。
| Animal Model: |
Swiss mice (female, 25-30 g, intestinal mucositis induced via intraperitoneal injection of Irinotecan 75 mg/kg on days 2-5 of an 8-day study) |
| Dosage: |
25 mg/kg; 75 mg/kg; 150 mg/kg |
| Administration: |
i.p.; daily for 8 days |
| Result: |
Achieved 87.5% survival at 25 mg/kg dose. Achieved 100% survival at 75 mg/kg dose. Achieved 87.5% survival at 150 mg/kg dose. Resulted in a body mass loss of 4.6 g over 7 days at 25 mg/kg dose. Resulted in a body mass loss of 4.4 g over 7 days at 75 mg/kg dose. Resulted in a body mass loss of 3.4 g over 7 days at 150 mg/kg dose. Restored leucocyte count to 5710 leucocytes/mm3 at 75 mg/kg dose, reversing CPT-11-induced neutropenia. Reduced bacterial load to levels comparable to DMSO-treated control mice at 75 mg/kg dose. Reduced histological injury scores to 0-2 at 75 mg/kg dose, compared to 3-4 in CPT-11-treated mice. Restored villi height to 185 μm and crypt depth to 86.5 μm at 75 mg/kg dose, reversing CPT-11-induced shortening. Restored Na+/K+-ATPase activity to 2156 μmol Pi/mg protein/h at 75 mg/kg dose, reversing CPT-11-induced reduction. Reduced myeloperoxidase (MPO) activity to 1.16 U MPO/mg tissue at 75 mg/kg dose. Reduced pro-inflammatory cytokine levels to 148.4 pg/mL (IL-1β), 497.9 pg/mL (KC), and 46.24 pg/mL (TNF-α) at 75 mg/kg dose. Reduced immunostained cells for NF-κB to 23.58 and COX-2 to 12.14 at 75 mg/kg dose. Reduced malondialdehyde (MDA) to 111.8 nmol/mL and nitric oxide metabolites (NOx) to 0.24 μM at 75 mg/kg dose. Increased glutathione (GSH) to 610.5 μg/mL and superoxide dismutase (SOD) to 5.04 U SOD/μg at 75 mg/kg dose. |
| Animal Model: |
Swiss albino (female, average weight 25 g) |
| Dosage: |
500 mg/kg; 1000 mg/kg; 2000 mg/kg; 4000 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Determined an LD10 of 566.7 mg/kg. Determined an LD50 of 1544.5 mg/kg. Showed no behavioral changes in treated mice during the 15-day observation period. |
| Animal Model: |
Sheep (both sexes, 6-16 months old, average weight 18 kg) |
| Dosage: |
250 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Reduced fecal egg counts by 35.4% at 8 days post-treatment. Reduced fecal egg counts by 65.9% at 16 days post-treatment. Shifted nematode larvae composition from 90% Haemonchus spp., 7% Trichostrongylus spp., 3% Oesophagostumum spp. pre-treatment to 43% Haemonchus spp., 51% Trichostrongylus spp., 6% Oesophagostumum spp. at 16 days post-treatment. |
| Animal Model: |
Swiss albino (male, 25-30 g, 2 months old, Pilocarpine-induced epilepsy) |
| Dosage: |
100 mg/kg |
| Administration: |
i.p.; single dose; 30 minutes before Pilocarpine |
| Result: |
Reduced seizure incidence by 60% and mortality by 40% compared to Pilocarpine-only controls. Increased latency to first seizure by 340.55% compared to Pilocarpine-only controls. Increased hippocampal δ-ALA-D activity by 47.35% and Na+, K+-ATPase activity by 30.7% compared to Pilocarpine-only controls. Increased hippocampal GABA levels by 78.25% compared to Pilocarpine-only controls. Did not alter glutamate, aspartate, or glutamine levels relative to Pilocarpine-only controls. Had effects reversed by flumazenil. |
| Animal Model: |
Swiss albino (male, 25-30 g, 2 months old, pentylenetetrazol-induced epilepsy) |
| Dosage: |
100 mg/kg |
| Administration: |
i.p.; single dose; 30 minutes before pentylenetetrazol |
| Result: |
Reduced seizure incidence by 70% and mortality by 70% compared to pentylenetetrazol-only controls. Increased latency to first seizure by 345.96% compared to pentylenetetrazol-only controls. Increased hippocampal δ-ALA-D activity by 83.38% and Na+, K+-ATPase activity by 28% compared to pentylenetetrazol-only controls. Increased hippocampal GABA levels by 51.43% compared to pentylenetetrazol-only controls. Did not alter glutamate, aspartate, or glutamine levels relative to pentylenetetrazol-only controls. Had effects reversed by flumazenil. |
| Animal Model: |
Swiss albino (male, 25-30 g, 2 months old, Picrotoxin-induced epilepsy) |
| Dosage: |
100 mg/kg |
| Administration: |
i.p.; single dose; 30 minutes before Picrotoxin |
| Result: |
Reduced seizure incidence by 50% and mortality by 50% compared to Picrotoxin-only controls. Increased latency to first seizure by 163.67% compared to Picrotoxin-only controls. Increased hippocampal δ-ALA-D activity by 57.24% and Na+, K+-ATPase activity by 32.6% compared to Picrotoxin-only controls. Increased hippocampal GABA levels by 103% and reduced glutamine levels by 42.8% compared to Picrotoxin-only controls. Did not alter glutamate or aspartate levels relative to Picrotoxin-only controls. Had effects reversed by flumazenil. |
| Animal Model: |
Swiss albino (male, 25-30 g, 2 months old) |
| Dosage: |
100 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Produced no significant change in spontaneous locomotor activity compared to vehicle controls. Produced no significant change in motor coordination compared to vehicle controls. |
| Animal Model: |
Swiss albino (male, 2 months old, 25-30 g) |
| Dosage: |
25 mg/kg; 50 mg/kg; 75 mg/kg; 100 mg/kg |
| Administration: |
i.p.; single injection |
| Result: |
Reduced hippocampal thiobarbituric acid reactive substances (TBARS) levels by 65%, 70%, 72%, and 85% respectively compared to vehicle (p < 0.0001), and by 33%, 43%, 48%, and 71% respectively compared to ascorbic acid 250 mg/kg (p < 0.0001). Reduced hippocampal nitrite content by 78%, 82%, 85%, and 92% respectively compared to vehicle (p < 0.0001), and by 56%, 65%, 71%, and 85% respectively compared to ascorbic acid 250 mg/kg (p < 0.0001). Increased hippocampal reduced glutathione (GSH) levels by 26%, 33%, 40%, and 50% respectively compared to vehicle (p < 0.05 for 25, 50, 75 mg/kg; p < 0.001 for 100 mg/kg). Increased hippocampal glutathione peroxidase (GPx) activity by 49%, 52%, 71%, and 102% respectively compared to vehicle (p < 0.0001); the 75 mg/kg dose was superior to the 50 mg/kg dose (p < 0.001), and the 100 mg/kg dose was superior to the 75 mg/kg dose (p < 0.0001). Increased hippocampal catalase activity by 57%, 63%, 57%, and 88% respectively compared to vehicle (p < 0.0001). Did not significantly change hippocampal superoxide dismutase (SOD) activity at any tested dose compared to vehicle. |
|